

**Remarks**

The application is to be amended without prejudice or disclaimer as previously set forth, which should not be viewed as narrowing or limiting the claims. The amendments are sought to conform the application to a form more consistent with Office practice by removing multiple dependencies. It is respectfully submitted that no new matter has been added by the amendments. Should the Office determine that additional issues remain, which might be resolved by a telephone conference, it is respectfully invited to contact applicants' undersigned attorney.

Respectfully Submitted,



Allen C. Turner  
Registration Number 33,041  
Attorney for Applicants  
TRASKBRITT, PC  
P.O. Box 2550  
Salt Lake City, Utah 84110  
Telephone: (801) 532-1922

Date: November 6, 2001

Enclosure: Version With Markings to Show Changes Made

VERSION WITH MARKINGS TO SHOW CHANGES MADE

3. (Amended) The nucleic acid delivery vehicle of [claim 1 or] claim 2, wherein said tissue tropism is provided by at least a part of a virus capsid or a functional derivative and/or analogue thereof.
6. (Amended) The nucleic acid delivery vehicle of claim 4 [or claim 5], wherein at least one of said at least two different viruses is an adenovirus of subgroup B.
7. (Amended) The nucleic acid delivery vehicle of claim 4, [claim 5, or claim 6,] wherein at least one of said proteins comprises a tissue tropism determining part of a fiber protein derived from a subgroup B adenovirus a functional derivative and/or analogue thereof.
8. (Amended) The nucleic acid delivery vehicle of claim 6 [or claim 7], wherein said subgroup B adenovirus is adenovirus 16.
9. (Amended) The nucleic acid delivery vehicle of claim 6, [claim 7, or claim 8,] further comprising at least one protein derived from an adenovirus not belonging to subgroup B, or a functional part, derivative and/or analogue thereof.
11. (Amended) The nucleic acid delivery vehicle of [any one of claims 1 through 10]claim 3, further comprising adenoviral nucleic acid.
12. (Amended) The nucleic acid delivery vehicle of [any one of claims 1 through 11]claim 3, comprising adenoviral nucleic acid from at least two different adenoviruses.

13. (Amended) The nucleic acid delivery vehicle of claim 11 [or claim 12], wherein said adenoviral nucleic acid at least encodes a fiber protein comprising at least a tissue tropism determining part of a subgroup B adenovirus fiber protein or a functional derivative and/or analogue thereof.
14. (Amended) The nucleic acid delivery vehicle of claim 11, [claim 12 or claim 13,] wherein said adenoviral nucleic acid is a modified nucleic acid such that the capacity of said adenoviral nucleic acid to replicate in a target cell has been reduced or disabled.
15. (Amended) The nucleic acid delivery vehicle of [any one of claims 11 through 14]claim 12, wherein said adenoviral nucleic acid is a modified nucleic acid such that the capacity of a host immune system to mount an immune response against adenovirus proteins encoded by said adenoviral nucleic acid has been diminished.
16. (Amended) The nucleic acid delivery vehicle of [any one of claims 1 through 15,]claim 3 further comprising a minimal adenovirus vector or an Ad/AAV chimeric vector.
17. (Amended) The nucleic acid delivery vehicle of [any one of claims 1 through 16,]claim 3 further comprising at least one nucleic acid of interest.
18. (Amended) The nucleic acid delivery vehicle of [any one of claims 1 through 17]claim 3, wherein said nucleic acid delivery vehicle is a subgroup B adenovirus capsid comprising at least one nucleic acid of interest.
21. (Amended) The nucleic acid delivery vehicle of claim 18, [claim 19, or claim 20,] wherein said subgroup B adenovirus capsid is derived from adenovirus 16.

22. (Amended) A process for producing the nucleic acid delivery vehicle of [any one of claims 1 through 21]claim 3, said method comprising:

providing a cell with means for the assembly of said nucleic acid delivery vehicle wherein said means includes a means for the production of an adenovirus fiber protein, wherein said adenovirus fiber protein comprises at least a tissue tropism determining part of a subgroup B adenovirus or a functional derivative and/or analogue thereof.

23. (Amended) A cell for the production of the nucleic acid delivery vehicle of [any one of claims 1 through 21]claim 3, said cell comprising:

means for the assembly of said nucleic acid delivery vehicle wherein said means includes a means for the production of an adenovirus fiber protein, wherein said adenovirus fiber protein comprises at least a tissue tropism determining part of a subgroup B adenovirus fiber protein.

24. (Amended) A pharmaceutical preparation comprising the nucleic acid delivery vehicle of [any one of claims 1 to 21]claim 1.

26. (Amended) A method for the delivery of nucleic acid to mesenchymal stem cells comprising administering the nucleic acid delivery vehicle of [any one of claims 1 to 22]claim 1.

27. (Amended) A method for the generation of a nucleic acid library comprising analyzing the nucleic acid delivery vehicle of [any one of claims 1 to 21]claim 1.

29. (Amended) A pharmaceutical preparation for the treatment of rheumatoid arthritis comprising the nucleic acid delivery vehicle of [any one of claims 1 to 21]claim 1.

31. (Amended) A method for tissue engineering comprising administering the nucleic acid delivery vehicle of [any one of claims 1 to 22]claim 1.
32. (Amended) A pharmaceutical preparation for providing bone regeneration comprising the nucleic acid delivery vehicle of [any one of claims 1 to 22]claim 1.
33. (Amended) A pharmaceutical preparation for providing bone regeneration comprising a mesenchymal stem cell provided with a gene of interest through the nucleic acid delivery vehicle of [any one of claims 1 to 22]claim 1.
34. (Amended) The pharmaceutical preparation of claim 32 [or claim 33] wherein said nucleic acid delivery vehicle is provided with a gene encoding bone morphogenesis protein-2 and/or LIM mineralization protein-1 or a functional equivalent of either.
35. (Amended) A pharmaceutical preparation for the treatment of multiple sclerosis comprising a mesenchymal stem cell provided with a gene of interest through the nucleic acid delivery vehicle of [any one of claims 1-22]claim 1.
36. (Amended) A pharmaceutical preparation for promoting angiogenesis comprising a mesenchymal stem cell provided with a gene of interest through the nucleic acid delivery vehicle of [any one of claims 1-22]claim 1.
37. (Amended) A mesenchymal stem cell comprising a nucleic acid delivered to said mesenchymal stem cell through the nucleic acid delivery vehicle of [any one of claims 1-21]claim 1.